- Home
- ZENV vs NSPR Comparison
ZENV vs NSPR Comparison
Compare ZENV & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- NSPR
- Stock Information
- Founded
- ZENV 2005
- NSPR 2005
- Country
- ZENV Brazil
- NSPR Israel
- Employees
- ZENV N/A
- NSPR N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- NSPR Medical/Dental Instruments
- Sector
- ZENV Technology
- NSPR Health Care
- Exchange
- ZENV Nasdaq
- NSPR Nasdaq
- Market Cap
- ZENV 63.3M
- NSPR 63.0M
- IPO Year
- ZENV 2021
- NSPR N/A
- Fundamental
- Price
- ZENV $1.62
- NSPR $3.00
- Analyst Decision
- ZENV
- NSPR Strong Buy
- Analyst Count
- ZENV 0
- NSPR 2
- Target Price
- ZENV N/A
- NSPR $4.75
- AVG Volume (30 Days)
- ZENV 73.5K
- NSPR 79.0K
- Earning Date
- ZENV 11-18-2024
- NSPR 11-12-2024
- Dividend Yield
- ZENV N/A
- NSPR N/A
- EPS Growth
- ZENV N/A
- NSPR N/A
- EPS
- ZENV N/A
- NSPR N/A
- Revenue
- ZENV $173,594,726.00
- NSPR $6,821,000.00
- Revenue This Year
- ZENV $25.56
- NSPR $13.31
- Revenue Next Year
- ZENV $6.02
- NSPR $52.91
- P/E Ratio
- ZENV N/A
- NSPR N/A
- Revenue Growth
- ZENV 23.49
- NSPR 24.70
- 52 Week Low
- ZENV $1.00
- NSPR $1.81
- 52 Week High
- ZENV $3.88
- NSPR $3.42
- Technical
- Relative Strength Index (RSI)
- ZENV 54.93
- NSPR 57.02
- Support Level
- ZENV $1.61
- NSPR $2.80
- Resistance Level
- ZENV $1.78
- NSPR $3.01
- Average True Range (ATR)
- ZENV 0.12
- NSPR 0.20
- MACD
- ZENV -0.00
- NSPR -0.02
- Stochastic Oscillator
- ZENV 48.48
- NSPR 60.00
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create unique journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.